natgillin/translations-raw huggingface dataset:
the resulting precipitated N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]-benzamide is washed with water and ethanol, and is dried, and the precipitate is suspended into a mixture of ethanol and water and is heated up to a temperature of 40-90° C. for 1 to 10 hours, and 
€) dobiveni istaloženi N-(2-aminofenil)-4-[N-(piridin-3-il)metoksikarbonilaminometil|-benzamid ispire se sa vodom i etanolom, i 1) talog se suspendira u smjesi etanola i vode te se zagrijava do temperature od 40 - 90% tijekom 1 do 10 sati, te
A compound of claim 1, which is represented by Formula (I)(A) 
Spoj u skladu s patentnim zahtjevom 1, prikazan Formulom (I)(A) sE
Use according to claim 6 wherein the allergen is Fel D1 and the molecule comprises an antibody specific for Fel D1; wherein the molecule comprises at least a portion of an anti-Fel D1 antibody that specifically binds to Fel D1, fused to at least a portion of an IgG molecule. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što molekula sadrži u najmanju ruku dio protutijela protiv Fel D1 koje se specifično veže na Fel D1, fuzioniran s u najmanju ruku dijelom molekule IgG.
the fixing means (31, 31a) do not interfere with the catching means (33, 33a) of the latches when the latches are in their idle position such that the ladle shroud (111) is free to move away from the collector nozzle along the longitudinal axis, and 
sredstva za pričvršćivanje (31, 314) ne utječu na sredstva za zahvaćanje (33, 334) zasuna, kada su zasuni u svom položaju praznog hoda tako da se izljevnik (111) može odmaknuti od mlaznice kolektora duž uzdužne osi, -
The pharmaceutical composition according to claim 9, further comprising an antibacterial agent. 
Farmaceutski sastav u skladu s patentnim zahtjevom 10, nadalje obuhvaća antibakterijski agens.
L -Y-glutamyl-S-[(4-biphenylyl)methyl]- L -cysteinyl- D -phenylglycine, as the hydrochloride salt, was prepared from 330 mg N-a-(benzyloxycarbonyl)- L -Y-glutamyl- L -cysteinyl- D -phenylglycine by dissolving the amine-protected peptide in acetonitrile/water, adding an approximate 10-fold excess of sodium bicarbonate, and adding a slight excess of 4-(bromomethyl)biphenyl, then maintaining the reaction under nitrogen until completion. 
L-y-glutamil-S-[(4-bifenil)metil]-1-cisteinil-D-fenilglicin, kao hidrokloridna sol, pripravljen je iz 350 mg N-a- (benziloksikarbonil)- L-y-glutamil-1-cisteinil-D-fenilglicin otapanjem amino-zaštićenog peptida u acetonitril/voda, dodavanjem približno 10-crostruko veće količinc bikarbonata, i dodavanjem malog suviška 4-(bromomctil)bifenila, i nakon toga održavanjem reakcije do kraja pod dušikom.
adding cold water, stirring the resultant biphasic mixture for 20 minutes at 0°C, and isolating the crude trans-(±)-A9-tetrahydrocannabinol from the organic phase; 
dodavanja hladne vode, miješanja dobivene dvofazne smjese tijekom 20 minuta na 0°C, te izoliranja sirovog trans-(±)-A9-tertahidrokanabinola iz organske faze;
It is preferred that the excipients include at least one binder selected from hydroxypropyl cellulose, starch, in particular corn starch, pregelatinised starch and hydroxypropylmethyl cellulose. 
Poželjno je da ekscipijensi uključuju barem jedno vezivno sredstvo odabrano između hidroksipropilne celuloze, škroba, osobito škroba iz kukuruza, preželatiniziranog škroba i hidroksipropilmetilne celuloze.
For example, as shown in Figure 19, the 7-O-TES group may be removed from Formula 6 to give Formula 8 (where R1=R2=Ph; P1=TBDMS in generalized formula H of Scheme 3) or from Formula 7 to give Formula 9 (where R1=R2=Ph; P1=TBDMS; R7=CH3 in generalized formula H' of Scheme 3), respectively, using acetonitrile (ACN) and aqueous HF. 
Na primjer, kao što je prikazano na slici 19, 7-O-TES skupina može biti uklonjena iz formule 6 da bi se dobila formula 8 (gdje Ri=R>=Ph; P,STBDMS u općoj formuli H iz sheme 3), odnosno iz formule 7 da bi se dobila formula 9 (gdje R;=R>2=Plh; P,=STBDMS; R;=CH; u općoj formuli H' iz sheme 3), koristeći acetonitril (ACN) i vodeni HF.
R15 at each occurrence is independently selected from H, C1-C6 alkyl; 
R'* uvijek kada se pojavljuje je neovisno odabran od H, C;-Cg alkila;
R10B is selected from the group consisting of C1-4 alkyl, C3-4 cycloalkyl, cyclopropylmethyl, and cyclobutylmethyl, wherein the C1-4 alkyl of R10B is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, —OH, —CN, C1-4 alkoxy, and C1-4 haloalkoxy; and wherein each of the C3-4 cycloalkyl, cyclopropylmethyl, and cyclobutylmethyl of R10B is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, —OH, —CN, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxylalkyl, C1-4 alkoxy, and C1-4 haloalkoxy. 
B se bira iz skupine koju čine C1-4 alkil, C3-4 cikloalkil, ciklopropilmetil, te ciklobutilmetil, gdje C1-4 alkil u R10B može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje svaki od C3-4 cikloalkila, ciklopropilmetila, te ciklobutilmetila u R10B može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 alkoksi, te C1-4 halogenalkoksi.
In one aspect, the invention provides the use of a compound or pharmaceutical composition of formula I for the manufacture of a medicament for use in inhibiting a voltage-gated sodium channel. 
Spoj ili sol prema patentnom zahtjevu 5, naznačen time što je za upotrebu u postupku inhibicije voltažno-ovisnog natrijevog kanala kod subjekta.
The thieno[3,2-d]pyrimidine compound or its pharmaceutically acceptable salt of claim 1, wherein Z is NR3R4. 
Derivat tieno[3,2-d]pirimidina u skladu s patentnim zahtjevom 1, pri čemu Z je NRŽR* ili njegova farmaceutski prihvatljiva sol.
The dry powder inhaler of claim 1, wherein each cartridge powder compartment lateral vent tapers inwards towards the inner surface of the compartment so as to funnel the air as it passes through the vent into the compartment. 
Inhalator za suhi prah prema bilo kojem od prethodnih zahtjeva, naznačen time da se svaki bočni otvor odjeljka za prah za uložak (209, 309, 409, 509, 609, 709, 809) sužava prema unutra prema unutrašnjoj površini odjeljka (205, 305, 405, 505, 605, 705, 805) kako bi se vodio zrak dok prolazi kroz otvor u odjeljak.
Various types of microcrystalline cellulose of different particle size and of different density may freely be applied. 
Mogu se slobodni primjenjivati različiti tipovi mikrokristalne celuloze različite veličine čestica i različite gustoće.
When R13=hydrogen in formula X, then this position is protected prior to the coupling reaction and deprotected after the coupling reaction according to standard literature procedures with standard protection groups, e.g. 
Ako je R * = vodik u formuli X tada je ta pozicija zaštićena prije vezne reakcije 1 deprotektirana nakon vezne reakcije u skladu sa standardnim postupcima iz literature, standardnim protekcijskim grupama npr.
or salt thereof. The method of claim 1, wherein the condition is an inflammation related condition. The method of claim 1, wherein the condition is asthma, dermatitis, inflammatory bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease. 
Spoj formule (I), ili njegova sol, naznačen time što se upotrebljava za liječenje astme, dermatitisa, upalne bolesti crijeva, Alzheimerove bolesti, psihotične jake depresije, neuropatije, odbacivanja presatka, multiple skleroze, kroničnog uveitisa, kronične opstruktivne bolesti pluća, ili reumatoidnog artritisa.
Aluminium oxyhydroxide for use according to any one of claims 1 to 5, wherein aluminium oxyhydroxide is administered in an amount of 1.5 mg to 5.0 mg, preferably 1.5 to 3.0 mg, especially 1.5 to 2.5 mg, (given as Al2O3 equivalent) to an AD patient. 
Aluminijev oksihidroksid za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se aluminijev oksihidroksid primjenjuje na AD-pacijentu u količini od 1,5 mg do 5,0 mg, poželjno od 1,5 mg do 3,0 mg, i posebice od 1,5 mg do 2,5 mg (zadano u obliku ekvivalenta od Al2O3).
The composition of claim 1, further comprising a therapeutic agent selected from the group consisting of anesthetics, analgesics, anti-inflammatories, steroids, antibiotics, antiarthritics, anorectics, antihistamines and antineoplastics. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 14, nadalje sadrži terapijski agens odabran iz grupe koja se sastoji od anestetika, analgetika, protuupalnih lijekova, steroida, antibiotika, antiartritika, anorektika, antihistaminika 1 antineoplastika.
In the shown embodiment, the connection sleeve 8 comprises a flange 13 against which a rock plate 14 abuts. 
U prikazanoj izvedbi vezni rukavac 8 sadrži prirubnicu 13 o koju se upire ploča uz stijenu.
A fiber product for foodstuff packaging, comprising at least one first fiber layer, wherein the first fiber layer comprises cellulose fibers and the fiber product is card, board or paper, wherein the first fiber layer is at least partially interspersed with a filter material for binding mineral oil substances in such a manner that the fiber product has a migration value of at least less than 0.6 mg/kg., wherein said filter material is comprised of activated charcoal. 
Upotreba filtarskog materijala (6) u pakiranju živežnih namirnica, naznačena time što je u vlaknastom proizvodu (2, 2.1, 2.2, 2.3) razasut filtarski materijal (6) za vezanje tvari mineralnog ulja radi smanjivanja migriranja tvari mineralnog ulja iz vlaknastog proizvoda (2, 2.1, 2.2, 2.3) u drugi proizvod do vrijednosti migriranja od najmanje manje od 0,6 mg/kg, gdje je vlaknasti proizvod karton, ljepenka i/ili papir.
The method of claim 1, wherein supporting the one or more plants in each growing cradle further comprises planting one or more seeds in an inert growing medium. 
Postupak prema bilo kojem od zahtjeva 1 do 5 naznačen time da, održavanje jedne ili više biljaka u svakoj kolijevki za uzgoj (14) nadalje obuhvaća sadnju jedne ili više sjemenki u inertni medij za uzgoj.
A DNA molecule according to claim 3 wherein the polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO: 1 is given by SEQ ID NO: 11 and the polynucleotide sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2 is given by SEQ ID NO: 12. 
Molekula DNA u skladu s patentnim zahtjevom 3, naznačena time što je polinukleotidni slijed koji kodira polipeptid koji ima aminokiselinski slijed sa SEQ ID NO: 1 dan sa SEQ ID NO: 11, a polinukleotidni slijed koji kodira polipeptid koji ima aminokiselinski slijed sa SEQ ID NO: 2 je dan sa SEQ ID NO: 12.
A cover panel 6 is positioned in the recesses 4 of the wall elements 2 to cover the last side of the column 1. 
Pokrovna ploča 6 smješta se u udubljenja 4 zidnih elemenata 2 kako bi pokrila zadnju stranu stupa 1.
mixing the fine discrete precipitated divalent metal ion carbonate particles obtained in step (e) with an aqueous suspension of divalent metal ion hydroxide that was obtained by slaking high-purity divalent metal ion oxide in order to obtain a resulting reaction mixture; and 
miješanja finih diskretnih čestica istaloženog karbonata dvovalentnog metalnog iona dobivenog u koraku (e) s vodenom suspenzijom hidroksida dvovalentnog metalnog iona dobivenog gašenjem oksida dvovalentnog metalnog iona visoke čistoće ISO svjetline R457 od najmanje otprilike 94 %, što je izmjereno prema ISO 2469, kako bi se dobilo rezultirajuću reakcijsku smjesu;
The invention is directed to compounds according to Formula I: 
PATENTNI ZAHTJEVI Spoj u skladu s Formulom I:
An antibody produced by the hybridoma deposited as ATCC Deposit No. PTA-5817. 
Protutijelo, naznačeno time, da je proizvedeno od hybridoma deponiranog kao ATCC Depozit Br.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and 
Rg je odabran iz skupine koja se sastoji od vodika, alkila. arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila, 1 (NRcRp)sulfonila; a
The process of claim 4, wherein the resulting oxycodone base composition is suitable to be converted to an oxycodone hydrochloride composition having less than 25 ppm 14-hydroxycodeinone when reacted with hydrochloric acid. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 15 ppm.
The compound of claim 1, wherein R2 and R3 combine with the carbon to which they are attached to form optionally substituted homopiperazinyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R* i R* kombiniraju s ugljikom na kojeg su vezani kako bi tvorili izborno supstituirani homomorfolinil.
The pre-nozzle according to claim 1, characterized in that the water inlet opening of the pre-nozzle is expanded downwards and/or upwards to improve the water inflow. 
Pred-mlaznica prema zahtjevu 1, okarakterizirana time da je otvor za vodu (12) pred-mlaznice (10a, 10b, 10c) osobito proširen prema dolje i/ili gore da poboljša dotok vode.
the decoding device according to claim 4, wherein the decoding device decodes an encoded audio signal encoded by the encoding device. An audio signal encoding program for encoding an audio signal using first encoding means operating under a linear predictive coding scheme and second encoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal encoding program causing a computer device to function as: 
Kompjutorski program za kodiranje audio signala koji sadrži naredbe koje, kada ih se provodi na kompjutoru, uzrokuju da navedeni kompjutor kodira audio signal uz pomoć prvog kodera (13), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugog kodera (14), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što program za kodiranje audio signala uzrokuje da kompjutorski uređaj funkcionira kao:
The method according to claim 10 wherein a filling is also present inside said first region. 
Žvakaća guma prema patentnim zahtjevima 15 ili 16, naznačeno time da je unutar rečene prve regije također prisutno punilo.
A compound according to claim 2 wherein R′ is selected from a group consisting of phenyl group and thienyl group optionally substituted by one, two or three halogen atoms. 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što se R1 bira iz skupine koju čine fenilna skupina i tienilna skupina koja može biti supstituirana s jednim, dva ili tri atoma halogena.
A compound of any one of claims 1-10 or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of influenza virus infection in a patient. 
Spoj formule: [image] ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju gripe.
a sequence having at least 90% sequence identity to SEQ ID NO 2, wherein said sequence has lysosomal alpha-mannosidase activity. 
B) slijeda koji je najmanje 80% identičan slijedu u SEQ ID NO 2.
A process for the preparation of the compound claimed in claim 1, or a pharmaceutically acceptable salt thereof, which process comprises the reaction of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)piperidine-4-carboxamide with a bicyclic heterocycle of Formula (V): 
17. Postupak za pripravu spoja prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time da postupak sadrži = reakciju - (S)-4-amino-N-(1-(4-klorofenil)-3-hidroksipropil)piperidin-4-karboksamida sa = bicikličkim heterociklom sa Formulom (V)!:
a variable light chain comprising the CDRs 1, 2 and 3 of the amino acid sequence of SEQ ID NO: 1 and the CDRs 1, 2 and 3 of the amino acid sequence of SEQ ID NO: 3, and a variable heavy chain comprising the CDRs 1, 2 and 3 of the amino acid sequence of SEQ 1D NO: 2 and the CDRs 1, 2 and 3 of the amino acid sequence SEQ ID NO: 5. The bispecific antibody or antibody fragment thereof according to claim 1 that further comprises constant region domains, wherein the constant region domains preferably consist of CH1, CH2, CH3 and CL. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 1 IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLyB-Bi3-poveznica-VLyppp4.g-CL-C i dva teška lanca sa strukturom N-VHlip.Bi3-poveznica-V Hypp4-g-CH1-CH2-CH3-C, pri čemu VLip-pi3 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLyppa.g sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHip.pi3 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHhipna-s sadrži sekvencu aminokiseline SEQ ID NO: 4, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
n is selected from 1, and 2; and 
n je odabran od 1, i 2; i
is selected from the group consisting of phenyl(C1-3)alkyl, pyridinyl(C1-3)alkyl, and furanyl(C1-3)alkyl; wherein phenyl, pyridinyl, and furanyl are optionally substituted with one to three R11 substituents independently selected from the group consisting of C1-3alkoxy; tetrazolyl, C3-6cycloalkylaminocarbonyl; hydroxy(C1-4)alkylaminocarbonyl; C6-10arylaminocarbonyl wherein C6-10aryl is optionally substituted with carboxy or C1-4alkoxycarbonyl; morpholin-4-ylcarbonyl; chloro; fluoro; trifluoromethoxy; and carboxy; 
R! je izabran iz skupine koju čine fenil(C;.g)alkil, piridiniKC,.s)alkil i furani(C,.3)alkil; pri čemu fenil, piridinil i furanil su proizvoljno supstituirani sa jednim do tri R' supstituenta nezavisno izabrana iz skupine koju čine je C1salkoksi; tetrazolil, Cs.gcikloalkilaminokarbonil; hidroksi(C1.4)alkilaminokarbonil; C4_,oarilaminokarbonil pri čemu Cs.qaril je proizvoljno supstituiran sa karboksi ili C,galkoksikarbonil; morfolin-4-ilkarbonil; kloro; fluoro; trifluorometoksi, metoksikarbonil; i karboksi; uz uvjet da ne više od jedan R!! je Csroarilaminokarbonil,;
The solid-state lighting apparatus (100; 200; 300; 400; 500; 600; 700; 800; 900) of claim 1, further comprising a coated layer of copper sandwiched between the fixture (102; 402; 502; 602; 702; 802; 902) and an MCPCB, wherein the coated layer of copper prevents corrosion to the fixture. 
Rasvjetni uređaj, čvrstog oblika tijela (100; 200; 300; 400; 500; 600; 700; 800; 900) prema zahtjevu 1, naznačen time da sadrži jedan naneseni bakreni sloj, koji je postavljen između rasvjetnog tijela (102; 402; 502; 602; 702; 802; 902) i MCPCE, pri čemu naneseni sloj bakra sprječava koroziju rasvjetnog tijela.
g is 0, 1 or 2. The method of 1, wherein the compound is added directly to whole blood or packed cells extracorporeally. 
Spoj za uporabu prema patentnom zahtjevu 1, pri čemu se spoj ili njegova farmaceutski prihvatljiva sol dodaje direktno u cijelu krv ili eritrocite izvantjelesno.
The method of claim 1, wherein disease or condition associated with abnormal glycan biosynthesis, degradation, or accumulation is Gangliosidosis, and wherein the Gangliosidosis is Tay Sachs, Sandhoff, AB Variant, or GM-1 Gangliosidosis. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je bolest ili stanje povezano s abnormalnom biosintezom, razgradnjom ili nakupljanjem glikana gangliozidoza, te što je gangliozidoza Tay Sachsova, Sandhoffova, AB varijanta ili GM-I gangliozidoza.
to receive fluid from the first fluid source in that a fluid phase port of the first phase contact device (400) is in fluid communication with a fluid phase port of the second phase contact device (401) whereby fluid is able to flow from the first phase contact device to the second phase contact device; or 
A kako bi primili fluid iz prvog izvora fluida time što je otvor za fluidnu fazu prvog faznokontaktnog uređaja (400) u fluidnoj komunikaciji s otvorom za fluidnu fazu drugog faznokontaktnog uređaja (401) pri čemu fluid može teći iz prvog faznokontaktnog uređaja do drugog faznokontaktnog uređaja; ili
binds to human PD-1 with about the same KD as an antibody having a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid sequence of SEQ ID NO; 32; 
veže se za humani PD-1 sa oko istim KD kao antitijelo koje ima teški lanac koji sadrži aminokiselinsku sekvencu iz sekv. id. br.: 31 i lagani lanac koji sadrži aminokiselinsku sekvencu iz sekv. id. br.: 32;
The compound according to claim 1 or 2 which is characterized by a Raman spectroscopic pattern with peaks at values of 3072 cm-1, 3051 cm-1, 3029 cm-1, 3011 cm-1, 2909 cm-1, 2888 cm-1, 1245 cm-1, 824 cm-1, 747 cm-1 717 cm-1 and 194 cm-1. 
Spoj prema Zahtjevu 1 ili 2, naznačen time, da ima uzorak Ramanove spektroskopije s vršnim vrijednostima od 3072 cm, 3051 cm', 3029 cm", 3011 cm", 2909 cm'', 2888 cm'!, 1245 cm'', 824 cm, 747 cm, 717 cm! i 194 cm.
A compound according to claim 17 for use in the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemia and hypertension. 
Spoj prema zahtjevu 17, naznačen time, da je za uporabu u liječenju i profilaksi dijabetesa, pretilosti, poremećaja hranjenja, dislipidemije 1 hipertenzije.
reductive amination of the compound of formula 10 and a compound of formula 11: in the presence of a reducing agent to yield the compound of formula I, wherein azeotropic distillation of water is conducted at an elevated temperature prior to the addition of the reducing agent, and reductive amination is conducted at room temperature; 
NH NH, 0 (an u nazočnosti sredstva za redukciju kako bi se dobio spoj formule I, pri čemu se azeotropna destilacija vode izvodi pri povišenoj temperaturi prije dodavanja redukcijskog sredstva, a reduktivna aminacija se izvodi pri sobnoj temperaturi;
The volume is measured, and the moles of compound (e) are calculated prior to crystallization. 
Izmjeri se volumen, a molove spoja (e) izračuna se prije kristalizacije.
optionally dewatering the aqueous slurry; wherein at least one processing agent is added before, during or after said aqueous calcium carbonate containing mineral slurry of step a) is contacted with said acid of step b) and with said CO2 generated in situ and/or supplied externally of step c), and wherein the at least one processing agent is selected from the group consisting of ferrous sulfate, ferric sulfate, ferrous chloride, ferric chloride, aluminum sulfate, and/or their hydrated forms, and wherein the processing agent is added in amounts of up to 8 wt.% based on the dry weight of the slurry. 
proizvoljno uklanjanje vode iz vodene suspenzije; naznačen time da se barem jedno sredstvo za obradu dodaje prije, tijekom ili poslije dovođenja u kontakt navedene vodene suspenzije koja sadrži kalcijev karbonat koji sadrži mineral iz koraka a) s navedenom kiselinom iz koraka b) i s navedenim CO, nastalim na licu mjesta i/ili koji se dobavlja iz vanjskog izvora iz koraka c), te pri čemu se barem jedno sredstvo za obradu bira iz skupine koju čine željezni sulfat, željezov sulfat, željezni klorid, željezov klorid, aluminijev sulfat, i/ili njihovi hidratni oblici, te pri čemu se sredstvo za obradu dodaje u količinama sve do 8 tež.% na bazi suhe težine suspenzije.
The inner part may furthermore comprise means to retain such an element, which originally has been an integrated part of the inner part. 
Unutarnji dio može nadalje sadržavati sredstvo za držanje takvog elementa, koji je originalno bio integralni dio unutarnjeg dijela.
The titled compound is prepared analogously to 4-bromomethyl-2-fluoro-1-methanesulfonyl-benzene by replacing 3,4-difluorobenzaldehyde with 3-chloro-4-fluorobenzaldehyde. 
Naslovni spoj je proizveden analogno 4-brom-metil-2-fluor-1-metansulfonil-benzenu zamjenom 3,4-difluorbenzaldehida s 3-klor-4-fluor-benzaldehidom.